<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826615</url>
  </required_header>
  <id_info>
    <org_study_id>JHSeo_gabapentin</org_study_id>
    <nct_id>NCT03826615</nct_id>
  </id_info>
  <brief_title>Gabapentin Pretreatment for Staged Bilateral Cataract Operations</brief_title>
  <official_title>The Effect of Gabapentin Pretreatment on Hyperalgesia in Elderly Patients Undergoing Staged Bilateral Cataract Operations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of oral gabapentin premedication on hyperalgesia in elderly patients
      undergoing staged bilateral cataract operations under monitored anesthesia care
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been reported that patients with bilateral cataract complained more pain and
      discomfort during the second consecutive eye surgery compared to the first eye surgery.

      Gabapentin is an anticonvulsant drug, which has been extended the use to perioperative
      analgesia, and anxiolysis.

      Therefore, the investigators conducted this randomized, controlled study to evaluate the
      effects of gabapentin premedication on patients' subjective sensations, including
      intraoperative anxiety, perceptions of pain, and light sensitivity, in the second cataract
      operations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain perception</measure>
    <time_frame>during the operation</time_frame>
    <description>intraoperative pain perception evaluated by VAS in first and second cataract surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hyperalgesia</condition>
  <condition>Cataract Bilateral Nos</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin premedication group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No medication</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged over 60 years, who undergoing staged bilateral cataract operations under
             monitored anesthesia care

          -  ASA physical status of I, II, and III

        Exclusion Criteria:

          -  undergoing other eye operations together besides cataract operation

          -  patients with creatinin clearance lower than 30ml/min

          -  patients with CNS inhibitors medication

          -  patients with previous gabapentin medication

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Hwa Seo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong-Hwa Seo, MD</last_name>
    <phone>82-2-2072-2467</phone>
    <email>eongpa@empas.com</email>
  </overall_contact>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong-Hwa Seo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

